Daily Newsletter

27 May 2024

Daily Newsletter

Grey Wolf gains $50m boost for antigen modulation tech

The extended Series B funding surge propels the total Series B capital to $99m.

Vishnu Priyan May 24 2024

Grey Wolf Therapeutics has concluded an oversubscribed $50m in Series B financing expansion to advance its antigen modulation technology.

ICG's Life Sciences team spearheaded the Series B expansion, with support from current investors including Pfizer Ventures, Canaan, Andera Partners, Oxford Science Enterprises and Earlybird Venture Capital.

This funding propelled the total Series B capital to $99m.

The newly secured capital will be utilised to broaden the ongoing Phase I/II clinical trial scope of Grey Wolf's lead immuno-oncology candidate, GRWD5769, for solid tumour types.

An oral ERAP1 inhibitor, the candidate demonstrated promising results in eliciting a robust immune response against cancer cells.

The funds will facilitate the expansion of research and development efforts for the company’s antigen modulation technology into potential treatments for autoimmune diseases.

Grey Wolf is progressing with a second ERAP1 inhibitor, GRWD0715, which is currently in the preclinical stage, for autoimmune diseases.

This candidate is on track to enter clinical trials by 2025,

Life Sciences at ICG associate director Tracy Weightman joined the board of directors of Grey Wolf.

Grey Wolf Therapeutics CEO Peter Joyce stated: “The funds raised as part of this Series B expansion round allows us to enrich our ongoing clinical trial of GRWD5769 to include patients with a wider variety of tumour types and evaluate new combination treatment cohorts. In addition, the new capital enables us to more fully explore the breadth of potential therapeutic applications for our antigen modulation technology. 

“There is a wealth of supportive recent clinical research and compelling human genetic associations pointing to the potential for antigen modulation driven by ERAP inhibition to open the door for disease-modifying therapies in the field of autoimmune disease. As such, we are expanding our R&D efforts and evaluating these broader therapeutic applications for our unique technology.”

CMO Industry Analysis

GlobalData's latest report is the 14th edition offering an analysis of the CMO industry, using the FDA’s NDA approvals as the primary indicator of performance. The report is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. This year’s edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.

CMO Industry Analysis

GlobalData's latest report is the 14th edition offering an analysis of the CMO industry, using the FDA’s NDA approvals as the primary indicator of performance. The report is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. This year’s edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.

CMO Industry Analysis

GlobalData's latest report is the 14th edition offering an analysis of the CMO industry, using the FDA’s NDA approvals as the primary indicator of performance. The report is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. This year’s edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close